Loading...
•
Jun 30, 2020
Adicet Bio Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.
Key Takeaways
resTORbio reported a net loss of $5.6 million, or $0.15 per share, for the three months ended June 30, 2020. The company's cash and cash equivalents were $70.9 million as of June 30, 2020. They also entered into a definitive merger agreement with Adicet Bio to advance allogeneic gamma delta CAR-T cell technology.
Entered into a definitive merger agreement with Adicet Bio, Inc. to advance allogeneic gamma delta CAR-T cell technology.
Awarded a grant from the National Institute of Aging for a pilot study of RTB101 as COVID-19 prophylaxis in older adults.
Initiated a study of RTB101 to evaluate the role of antiviral prophylaxis in reducing the severity of COVID-19 in nursing home residents.
Net loss was $5.6 million, or $0.15 per share, for the three months ended June 30, 2020.